These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26947399)

  • 21. Effect of prophylactically applied CpG ODN on the development of myocarditis in mice infected with Coxsackievirus B3.
    Zhao T; Wu X; Song D; Fang M; Guo S; Zhang P; Wang L; Wang L; Yu Y
    Int Immunopharmacol; 2012 Dec; 14(4):665-73. PubMed ID: 23063973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012-2016.
    Wang J; Teng Z; Cui X; Li C; Pan H; Zheng Y; Mao S; Yang Y; Wu L; Guo X; Zhang X; Zhu Y
    Emerg Microbes Infect; 2018 Jan; 7(1):8. PubMed ID: 29362406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enterovirus 71 infection in children with hand, foot, and mouth disease in Shanghai, China: epidemiology, clinical feature and diagnosis.
    Wang Y; Zou G; Xia A; Wang X; Cai J; Gao Q; Yuan S; He G; Zhang S; Zeng M; Altmeyer R
    Virol J; 2015 Jun; 12():83. PubMed ID: 26036928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a enterovirus diagnostic assay system for diagnosis of viral myocarditis in humans.
    Lim BK; Ju ES; Lao DH; Yun SH; Lee YJ; Kim DK; Jeon ES
    Microbiol Immunol; 2013 Apr; 57(4):281-7. PubMed ID: 23586632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
    Fan X; Yue Y; Xiong S
    Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis.
    Tschöpe C; Müller I; Xia Y; Savvatis K; Pappritz K; Pinkert S; Lassner D; Heimesaat MM; Spillmann F; Miteva K; Bereswill S; Schultheiss HP; Fechner H; Pieske B; Kühl U; Van Linthout S
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28912259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole-genome analysis of coxsackievirus B3 reflects its genetic diversity in China and worldwide.
    Yang Q; Yan D; Song Y; Zhu S; He Y; Han Z; Wang D; Ji T; Zhang Y; Xu W
    Virol J; 2022 Apr; 19(1):69. PubMed ID: 35436962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immune effects of four coxsackievirus B3 VP1 DNA fusion vaccines in mice].
    Liu GX; Lan JM; Chuai X; Gao ZY; Jin YH; Zhang YH; Xie LX; Yin CF; Wang YX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Feb; 26(2):103-6. PubMed ID: 20230664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of neutralizing antibodies against HFMD associated enteroviruses among healthy individuals in Shanghai, China, 2022.
    Wang J; Wu W; Wang W; Zhang J; Xiao J; Cai M; Guo J; Li R; Zhu S; Zhang W; Chen M; Teng Z
    Virol Sin; 2024 Aug; 39(4):694-698. PubMed ID: 38801978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon.
    Chehadeh W; Lobert PE; Sauter P; Goffard A; Lucas B; Weill J; Vantyghem MC; Alm G; Pigny P; Hober D
    J Virol; 2005 Nov; 79(22):13882-91. PubMed ID: 16254324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the epidemiological characteristics of EV71 and CVA16 infection to aid the diagnosis and treatment of hand, foot, and mouth disease.
    Wang B; Li J; Wang Y; Du N; Sun L; Xiao H; Zhao Y; Bao W; Zhang W
    J Med Virol; 2019 Feb; 91(2):201-207. PubMed ID: 30118553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two models for changes of EV71 immunity in infants and young children.
    Tu X; Wang Y; Zhu F; Chen F
    Hum Vaccin Immunother; 2015; 11(6):1429-33. PubMed ID: 25906390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enterovirus 71 Neutralizing Antibodies Seroepidemiological Research among Children in Guangzhou, China between 2014 and 2015: A Cross-Sectional Study.
    Zhang D; Chen Y; Chen X; He Z; Zhu X; Hao Y
    Int J Environ Res Public Health; 2017 Mar; 14(3):. PubMed ID: 28335535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.
    Slifka MK; Pagarigan R; Mena I; Feuer R; Whitton JL
    J Virol; 2001 Mar; 75(5):2377-87. PubMed ID: 11160741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.
    Dan M; Chantler JK
    J Virol; 2005 Jul; 79(14):9285-95. PubMed ID: 15994822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmission and serotype features of hand foot mouth disease in household contacts in Dong Thap, Vietnam.
    Hoang CQ; Nguyen TTT; Ho NX; Nguyen HD; Nguyen AB; Nguyen THT; Phan HC; Phan LT
    BMC Infect Dis; 2019 Nov; 19(1):933. PubMed ID: 31690269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice.
    Koho T; Koivunen MR; Oikarinen S; Kummola L; Mäkinen S; Mähönen AJ; Sioofy-Khojine A; Marjomäki V; Kazmertsuk A; Junttila I; Kulomaa MS; Hyöty H; Hytönen VP; Laitinen OH
    Antiviral Res; 2014 Apr; 104():93-101. PubMed ID: 24485896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis.
    Li M; Yan K; Wei L; Yang J; Lu C; Xiong F; Zheng C; Xu W
    Antiviral Res; 2015 Nov; 123():50-61. PubMed ID: 26343012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population.
    Zhu R; Cheng T; Yin Z; Liu D; Xu L; Li Y; Wang W; Liu J; Que Y; Ye X; Tang Q; Zhao Q; Ge S; He S; Xia N
    Emerg Microbes Infect; 2018 Jan; 7(1):2. PubMed ID: 29323107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.
    Zautner AE; Körner U; Henke A; Badorff C; Schmidtke M
    J Virol; 2003 Sep; 77(18):10071-7. PubMed ID: 12941917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.